Joerg Trojan

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Medicine, Oncology, Pharmacology +11

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Fluorine-18 Fdg Positron Emission Tomography for Imaging of Hepatocellular Carcinoma

Joerg Trojan, Oliver C. Schroeder, Jochen Raedle et al. · The American Journal of Gastroenterology · 1999 · 270 citations

Medicine, Nuclear Medicine, Radiology +17

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Richard D. Kim, Debashis Sarker, Tim Meyer et al. · Cancer Discovery · 2019 · 250 citations · Full text

Medicine, Oncology, Pharmacology +17

Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system

Joerg Trojan, Stefan Zeuzem, Ann Randolph et al. · Gastroenterology · 2002 · 213 citations · Full text

Life Sciences, Genetics, Molecular Biology +10